TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00218946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 30 % sucrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 30 % sucrose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacifier

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacifier

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacifier

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sterile water
Study: NCT04337398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks (wearables)
Description: Activity trackers with adaptive weekly step goals, weekly walking groups and coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks (wearables and exergames)
Description: Activity trackers with adaptive weekly step goals, weekly walking groups, coaching and exercise programme based on exergames (aerobic, resistance and stretching training three weekly group sessions).
Study: NCT00593515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family cognitive behavioral therapy
Description: 12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
Study: NCT03457012

Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study: NCT02582840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose
Study: NCT00593515

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-focused cognitive behavioral therapy
Description: 12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
Study: NCT03014154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Study: NCT01096862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01998919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: 1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: 5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: 5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
Study: NCT03866213

Intervention type: DIAGNOSTIC_TEST
Intervention: BiliSpec
Description: BiliSpec will quantitatively measure the bilirubin content of a neonatal blood sample.
Study: NCT04537884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX1325
Description: Investigational drug intravitreal injection
Study: NCT03839628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Physical Activity
Description: Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
Study: NCT01302743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Metformin
Description: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 2: Cinnamon Bark
Description: Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 3: Cinnulin PF
Description: Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
Study: NCT03525704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline Solution Enriched
Description: Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline Rinse Solution
Description: sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i
Study: NCT00665405

Intervention type: RADIATION
Intervention: CT scan
Description: Thoracic CT scan

Intervention type: RADIATION
Intervention: CT scan
Description: Thoracic CT scan
Study: NCT02547012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole+amox+levo+tetra
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
Study: NCT00491322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 50000 international units once a week for 12 weeks
Study: NCT02547012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole+amox+levo
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
Study: NCT01444339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 1
Description: 0.5 mL, intramuscular (1 middle dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 2
Description: 0.5 mL, intramuscular (2 low doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 3
Description: 0.5 mL, intramuscular (2 middle doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 4
Description: 0.5 mL, intramuscular (2 middle doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 5
Description: 0.5 mL, intramuscular (2 high doses)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL, intramuscular
Study: NCT03644342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirapaib
Description: (see treatment regimen and method of treatment assignment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirapaib
Description: (see treatment regimen and method of treatment assignment)
Study: NCT03711097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanish XT Dental Varnish
Description: Varnish will be applied to the front surface of the intervention upper central and lateral incisors
Study: NCT03099031

Intervention type: DRUG
Intervention: Tinzaparin
Description: Subcutaneous injection of 175 IU/kg once daily for 6 months
Study: NCT04670328

Intervention type: DIAGNOSTIC_TEST
Intervention: not required
Description: Diagnostic tests( hematological parameters) were assessed.
Study: NCT03360383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous vertebroplasty
Description: Undertake Percutaneous vertebroplasty with polymethylmetacrylate bone cement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: complete on bed with prevention of complications
Study: NCT00491322

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ergocalciferol placebo
Description: Ergocalciferol placebo once a week for 12 weeks
Study: NCT00648583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Tablets 24 mg
Description: 24mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran® Tablets 24 mg
Description: 24mg, single dose fed
Study: NCT02277548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica 300 mg
Description: Lyrica 300 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02513095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium for injectable suspension
Description: Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
Study: NCT04530422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir plus Ledipasvir
Description: Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus Ledipasvir
Description: Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.
Study: NCT04762316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-UF
Description: Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SB-UF Placebo
Description: Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy.
Study: NCT02705664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl Nail Lacquer
Description: Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urea Ointment
Description: Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifonazole Cream
Description: Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
Study: NCT04483570

Intervention type: PROCEDURE
Intervention: Redo-tethering operation
Study: NCT04517630

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic
Description: Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
Study: NCT02582840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet. Oral dose
Study: NCT04973761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zirconium crowns
Description: Prefabricated pirmary anteroir teeth zirconium crowns

Intervention type: OTHER
Group type: OTHER
Intervention: Strip composite crowns
Description: Strip composite crowns
Study: NCT00293384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 80mg once daily in the morning on days 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron hydrochloride
Description: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
Study: NCT03998124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer facilitator training
Description: Peer facilitation of a project-based activity without staff present

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Staff-led social activity
Study: NCT01431807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: oral, for up to 52 weeks.
Study: NCT04456998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002 (seralutinib)
Description: Capsule containing GB002 (seralutinib)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule containing placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
Study: NCT04067505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
Study: NCT02579473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-214
Description: SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-214
Description: SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-214
Description: SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
Study: NCT03022149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate® (200mmHg)
Description: Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Doctormate® (60mmHg)
Description: Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
Study: NCT02897739

Intervention type: PROCEDURE
Intervention: Magnetic resonance imaging
Description: Cardiac MRI and short MRI following USPIO infusion

Intervention type: PROCEDURE
Intervention: Magnetic resonance imaging
Description: Cardiac MRI and short MRI following USPIO infusion

Intervention type: BIOLOGICAL
Intervention: Acute Inflammatory Activation study
Description: Blood sampling for exploration of type and level of inflammatory response

Intervention type: BIOLOGICAL
Intervention: Acute Inflammatory Activation study
Description: Blood sampling for exploration of type and level of inflammatory response

Intervention type: RADIATION
Intervention: PET CT
Description: PET study for metabolic pathway study

Intervention type: RADIATION
Intervention: PET CT
Description: PET study for metabolic pathway study

Intervention type: BEHAVIORAL
Intervention: Psychological assessment
Description: Assessment by a psychologist

Intervention type: BEHAVIORAL
Intervention: Psychological assessment
Description: Assessment by a psychologist
Study: NCT02837887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavior Therapy
Description: Undergo computerized cognitive behavior therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavior Therapy
Description: Undergo computerized cognitive behavior therapy
Study: NCT05112497

Intervention type: OTHER
Intervention: No intervention procedure
Description: No intervention procedure

Intervention type: OTHER
Intervention: No intervention procedure
Description: No intervention procedure
Study: NCT03652298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory structuring intervention + Vagal breathing
Description: The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation

Intervention type: OTHER
Group type: OTHER
Intervention: support and attention (usual care)
Description: support and attention (usual care)
Study: NCT01823029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enteral nutrition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enteral nutrition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of iron
Study: NCT01594593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: group-based behavioral workshop to address cancer-related distress
Study: NCT02398539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 0.5% cream
Study: NCT03529942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Extended-release 32 mg FX006 IA injection
Study: NCT02426281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
Study: NCT00145509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asenapine
Description: Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
Study: NCT02880982

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly oral placebo softgel capsule
Study: NCT02459756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage: Spray dried blackcurrant powder dissolved in water
Study: NCT02579473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-214
Description: SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
Study: NCT03261414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A short preanesthetic hypnosis before induction of anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Standard care before induction of anesthesia
Study: NCT04173507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO
Study: NCT04091516

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low-fat plant-based diet
Description: Participants will follow a diet that consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
Study: NCT03963193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.
Study: NCT02218138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning 2 BREATHE
Description: Mindfulness-based group program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorado Blues
Description: Colorado Blues, Cognitive-behavioral depression prevention group
Study: NCT04089579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Tissue Mesenchymal Stromal Cells
Description: Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Placebo comparative infusion
Study: NCT01823861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention
Description: Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.